Alzamend Neuro Inc stock is traded at $0.7758, with a volume of 92,031. It is down -23.94% in the last 24 hours and down -40.32% over the past month. Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Previous Close:
$1.02
Open:
$1.00
24h Volume:
92,031
Relative Volume:
2.33
Market Cap:
$3.74M
Revenue:
-
Net Income/Loss:
-$7.04M
P/E Ratio:
-
EPS:
-$4.38
Net Cash Flow:
-$6.17M
1W Performance:
-37.44%
1M Performance:
-40.32%
6M Performance:
-35.35%
1Y Performance:
-60.62%
1-Day Range:
$0.7536$1.00
1-Week Range:
$0.7536$1.30
52-Week Range:
$0.7536$2.54
Alzamend Neuro Inc Stock (ALZN) Company Profile
Name
Alzamend Neuro IncSector
HealthcareIndustry
BiotechnologyPhone
844-722-6333Address
480 PEACHTREE ROAD NE, SECOND FLOOR, ATLANTA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS